Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

151.33 +1.72 (+1.15%)
Official Closing Price Updated: 7:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease
Johnson & Johnson's Tremfya gains FDA approval for Crohn's disease, backed by Phase 3 trial data and demonstrating superiority over Stelara in key endpoints. 
Via Benzinga
Exposures Product Safety
Johnson & Johnson To Invest $55 Billion In US To Boost Manufacturing, Drug Discovery
Johnson & Johnson has announced a $55 billion investment in the U.S. over the next four years. This move will boost American manufacturing, research, and development, creating high-tech jobs and... 
Via Benzinga
Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years
From Johnson & Johnson
Via Business Wire
Two Sectors Just Tried And Failed - And That’s Great For Us
Technology and healthcare have both tried for a breakout and failed, courtesy of massive economic forces rocking the boat. 
Via Talk Markets
Topics Stocks / Equities
Johnson & Johnson Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Historic Dividend Outperformance
One of the most well-known dividend strategies is owning Dividend Aristocrats, of which the NOBL ETF tracks. 
Via Talk Markets
Topics ETFs Stocks / Equities
Johnson & Johnson's Golden Cross: Technical Momentum Meets Groundbreaking Lung Cancer Breakthrough
JNJ stock hits Golden Cross, signaling potential long-term upside. Latest breakthrough in lung cancer treatment could provide additional catalyst. 
Via Benzinga
Honeywell Isn't Going to Let a Little Breakup Ruin Its Growth Plans
Via The Motley Fool
Alpha Cognition Is 'Under-Followed' As Alzheimer Drug Targets $2 Billion Long Term Care Market: Analyst
HC Wainwright initiated coverage on Alpha Cognition, noting a new twist on a tried-and-tested treatment paradigm. 
Via Benzinga
FDA Grants Fast Track Review To Johnson & Johnson's Nipocalimab For Autoimmune Disorder That Affects Tears, Saliva
Johnson & Johnson's nipocalimab receives FDA Fast Track status for Sjögren's disease, following strong Phase 2 trial results on disease activity and IgG reduction. 
Via Benzinga
Exposures Product Safety
Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding Burden
Nanobiotix amended its $2.7 billion licensing deal with Johnson & Johnson, reducing costs while retaining key milestone payments. The update extends its cash runway to mid-2026. 
Via Benzinga
Got $300? Buy These 3 Top Dividend Stocks and Never Look Back.
Via The Motley Fool
Resilient Investing: 3 Stocks Built to Weather Market Volatility
Resilient companies with strong financials and diverse revenue in healthcare, technology, and essential services can offer stability in volatile markets. 
Via MarketBeat
Topics Economy
Exposures COVID-19 Economy
The S&P 500 Is in Correction Territory: 4 Surefire Stocks to Buy Right Now
Amazing deals abound within Wall Street's benchmark index. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Coinbase, Apple And Robinhood Are Among Top Large-Cap Losers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio?
Large-cap stocks worst performers last week: TER, TTD, COIN, SAIL, GMAB, IBKR, DAL, ADBE, EXPE, HOOD, UAL, AAPL. Are they in your portfolio? 
Via Benzinga
Allegations of Inflated Prescription Drug Costs Spark Employee Lawsuit Against JPMorgan
A lawsuit has been lodged against JPMorgan Chase by its employees, who claim that the company's prescription drug plan consented to pay exorbitant prices for medications. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Kroger CEO Shake-Up
Via The Motley Fool
Cool, Calm, and Collected: 2 Dividend ETFs to Buy During the S&P 500 Sell-Off
Via The Motley Fool
Topics ETFs Stocks
Exposures US Equities
Generate Passive Income From This Low-Cost Vanguard ETF That Is Crushing the S&P 500 in 2025
Via The Motley Fool
Topics ETFs Stocks
Exposures US Equities
Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at branded pharmaceuticals stocks, starting... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Vanguard High Dividend Yield ETF vs Vanguard Dividend Appreciation ETF: Which Is Best for You?
Vanguard has some excellent dividend ETFs, but they are right for different investors. 
Via The Motley Fool
Topics ETFs
Are High-Yield Dividend Stocks Best For Income-Focused Investors?
When selecting dividend-paying stocks, one of the first things that investors look at is, of course, the annual yield. But are high-yield stocks always the best route for income-focused investors?... 
Via Talk Markets
Topics Stocks / Equities
How Exxon Mobil, Johnson & Johnson, And Cogent Communications Can Put Cash In Your Pocket
Via Benzinga
2025 March Market Cap Showdown: Andy Cross vs. Matt Argersinger
Via The Motley Fool
Why Is Protagonist Therapeutics Stock Trading Higher On Monday?
Protagonist and Johnson & Johnson's treatment for ulcerative colitis and psoriasis studies met key endpoints. 
Via Benzinga
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out
The company is looking to take on Bristol Myers Squibb's Sotyktu in plaque psoriasis treatment. 
Via Investor's Business Daily
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
3 Dividend Kings Shaking Off Market Woes
The market has thrown a tantrum over recent weeks following tariff news and other economic data pointing to a slowing consumer base. While it’s certainly been a turbulent period, several stocks have... 
Via Talk Markets
Topics Stocks / Equities World Trade
Exposures Tariff
Johnson & Johnson Stops Late-Stage Depression Study Over 'Insufficient Efficacy'
Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato sales hit $1.01 billion 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.